| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Institutional press release |
| Population | Men and women |
| Source | BMJ Group (news release) |
| URL | bmjgroup.com/?p=18431 (opens in a new tab) |
Specific Claim Evaluated
Rapid growth in private testosterone prescribing could extend treatment to people with vague symptoms and borderline results, for whom the balance of benefit and long-term risk is less certain, while testosterone remains valuable for carefully selected patients.
Primary Research Supporting or Contradicting the Claim
Guidelines recommend testosterone only for men with consistent symptoms and signs and unequivocally low testosterone (Bhasin et al., 2018), and the only evidence-based indication in women is hypoactive sexual desire disorder (Davis et al., 2019).
Corrected Evidence-Based Interpretation
The release is correct. It describes an editorial opinion, not new research.
Rationale for Grade
The release identifies the source as an editorial that was not externally peer reviewed and presents its argument consistently with guidance on diagnosis in men and indication in women.
References
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID
Supporting excerpt: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs" - Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD."